. 2018 Aug 14;25(4):e324–e334. doi: 10.3747/co.25.3976

TABLE III.

Selected clinical trials of PD-1/PD-L1 inhibitors as combination therapy non-small-cell lung cancer (NSCLC)

Study name	Drug	Phase	Treatment	Population	Survival (months)		Response rate (%)

					Progression-free	Overall
CheckMate 012⁸⁰	Nivolumab 10 mg/kg with gemcitabine–cisplatin	I	First line	56 Advanced NSCLC randomized based on histologic type	24-Week rate: 51%	2-year rate: 25%	33
	Nivolumab 10 mg/kg with pemetrexed–cisplatin				24-Week rate: 71%	2-year rate: 33%	47
	Nivolumab 10 mg/kg with paclitaxel–carboplatin				24-Week rate: 38%	2-year rate: 27%	47
	Nivolumab 5 mg/kg with paclitaxel–carboplatin				24-Week rate: 51%	2-year rate: 62%	43
CheckMate 012⁸¹	Nivolumab 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 12 weeks	I	First line	77 Advanced NSCLC	8.1	Not reached	38
CheckMate 012⁸¹	Nivolumab 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks				3.9	Not reached	47
KEYNOTE 021⁸²	Paclitaxel–carboplatin	I/II	First line	123 Advanced NSCLC, no EGFR or ALK mutation	8.9	20.9	32
KEYNOTE 021⁸²	Pembrolizumab with paclitaxel–carboplatin				19.0 (HR: 0.54; p=0.0067)	Not reached (HR: 0.59; p=0.0344)	57
KEYNOTE 021⁸³	Pembrolizumab with pemetrexed–carboplatin	II	First line	123 Advanced nonsquamous NSCLC, no EGFR or ALK mutation	13.0	13	55
KEYNOTE 021⁸³	Pemetrexed–carboplatin				8.9 (HR: 0.53; p=0.01)	14 (HR: 0.90; p=0.39)	29
KEYNOTE 189⁸⁴	Pembrolizumab with pemetrexed–platinum agent	III	First line	616 Advanced nonsquamous NSCLC, no EGFR or ALK mutations	8.8	Not reached	48
KEYNOTE 189⁸⁴	Pemetrexed-platinum agent				4.9 (HR: 0.52; p<0.001)	11.3 (HR: 0.49; p<0.001)	19